Abstract
Parkinson’s disease (PD) is a complex neurodegenerative disease with a range of causes and clinical presentations. Over 76 genetic loci (comprising 90 SNPs) have been associated with PD by the most recent GWAS meta-analysis. Most of these PD-associated variants are located in non-coding regions of the genome and it is difficult to understand what they are doing and how they contribute to the aetiology of PD. We hypothesised that PD-associated genetic variants modulate disease risk through tissue-specific expression quantitative trait loci (eQTL) effects. We developed and validated a machine learning approach that integrated tissue-specific eQTL data on known PD-associated genetic variants with PD case and control genotypes from the Wellcome Trust Case Control Consortium, the UK Biobank, and NeuroX. In so doing, our analysis ranked the tissue-specific transcription effects for PD-associated genetic variants and estimated their relative contributions to PD risk. We identified roles for SNPs that are connected with INPP5P, CNTN1, GBA and SNCA in PD. Ranking the variants and tissue-specific eQTL effects contributing most to the machine learning model suggested a key role in the risk of developing PD for two variants (rs7617877 and rs6808178) and eQTL associated transcriptional changes of EAF1-AS1 within the heart atrial appendage. Similarly, effects associated with eQTLs located within the brain cerebellum were also recognized to confer major PD risk. These findings warrant further mechanistic investigations to determine if these transcriptional changes could act as early contributors to PD risk and disease development.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
WS, SF, AC, and JO were funded by the Michael J. Fox Foundation for Parkinsons research and the Silverstein Foundation for Parkinsons with GBA (grant ID 16229 to JOS). SF was funded by a Liggins Institute Doctoral Scholarship and Dines Family Trust. AC received grant funding from the Australian government. DH was funded by an MBIE Catalyst grant (The New Zealand-Australia Life-Course Collaboration on Genes, Environment, Nutrition and Obesity (GENO); UOAX1611; to JOS).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The University of Auckland Human Participants Ethics Committee Application (UAHPEC19373)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Relevant conflicts of interest/financial disclosure: Nothing to report.
Funding sources: WS, SF, AC, and JO were funded by the Michael J. Fox Foundation for Parkinson’s research and the Silverstein Foundation for Parkinson’s with GBA – grant ID 16229 to JOS. SF was funded by a Liggins Institute Doctoral Scholarship and Dines Family Trust. AC received grant funding from the Australian government. DH was funded by an MBIE Catalyst grant (The New Zealand-Australia Life-Course Collaboration on Genes, Environment, Nutrition and Obesity (GENO); UOAX1611; to JOS).
Data Availability
The data that support the findings of this study are available from the following resources in the public domain: The SNPs are listed in Supplementary table 1. The HiC datasets are listed in Supplementary table 2. eQTL information from 49 human tissues were obtained from the Genotype-Tissue Expression database [GTEx] v8; www.gtexportal.org PD genotype datasets were acquired from the: Wellcome Trust Case Control Consortium (Request ID 10584); UKBioBank (Application Number 61507); NeuroX-dbGap (dbGap project#98581-1)
